Clin2
NCT05366478Possibly a fitRecruiting

LM103 for advanced solid tumors using donated immune cells

MelanomaNon Small Cell Lung CancerCervical Carcinoma

Treatments studied

Part of Cancer, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
15 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have stage III or IV melanoma, non-small cell lung cancer, cervical cancer, or another solid tumor confirmed by biopsy, and standard options aren’t working or there is no standard option
  • Your doctors can take a tumor sample for testing (biopsy or surgery) and there is enough tissue available (more than 1.5 cm³)
  • Your blood counts are in a safer range (including enough white blood cells, platelets, and hemoglobin)
  • Your heart and organ function are strong enough (heart pumping—LVEF—at least 50%, plus liver and kidney blood tests not too high)
  • Your physical functioning is fairly good (ECOG 0–1) and you’re expected to live more than 3 months

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07028008Not yet recruiting
TIL therapy for advanced melanoma after immunotherapy

This trial tests a personalized cell therapy using your own immune cells (TILs) grown in a lab. It is for people with advanced melanoma that did not respond to or stopped responding to prior immunotherapy.

NCT06455917Recruiting· Phase 2
Personalized immune cell therapy for advanced lung cancer

This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.

Basel, Canton of Basel-City
NCT06695689Recruiting· Early Phase 1
LM303 injection for advanced solid tumors

This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.

Tianjin
NCT07310784Recruiting· Phase 2
Testing LM103 for advanced melanoma

This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.

Beijing, Beijing Municipality
NCT06941818Enrolling by invitation· Phase 1
TIL therapy for advanced melanoma

This trial tests a new cell therapy made from your own tumor-fighting cells (TILs) for advanced melanoma that hasn't responded to other treatments. It aims to shrink tumors by re-infusing these boosted cells back into your body.

Beijing
NCT05971576Not yet recruiting· Early Phase 1
TIL cell therapy for advanced solid tumors

This early-stage trial tests a type of immune cell treatment (TILs) made from your tumor to treat advanced solid cancers. It may help if standard treatments have failed or aren’t an option, but you must be able to provide enough tumor tissue for cell collection.

Hear when a new Melanoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.